{"protocolSection": {"identificationModule": {"nctId": "NCT02617446", "orgStudyIdInfo": {"id": "CVT-CV-002"}, "secondaryIdInfos": [{"id": "2013-000540-26", "type": "EUDRACT_NUMBER"}, {"id": "2015L00219", "type": "OTHER", "domain": "National Medical Products Administration (China)"}], "organization": {"fullName": "Windtree Therapeutics", "class": "INDUSTRY"}, "briefTitle": "The Clinical Study of the Safety and Efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure", "officialTitle": "The Clinical Study of the Safety and Efficacy of Istaroxime in Treatment of Acute Decompensated Heart Failure - A Multicenter, Randomized, Double-blind, Placebo Controlled, Parallel Group Clinical Study"}, "statusModule": {"statusVerifiedDate": "2023-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-12"}, "primaryCompletionDateStruct": {"date": "2018-08-14", "type": "ACTUAL"}, "completionDateStruct": {"date": "2019-02-06", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-07-09", "studyFirstSubmitQcDate": "2015-11-25", "studyFirstPostDateStruct": {"date": "2015-12-01", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2023-03-02", "resultsFirstSubmitQcDate": "2023-04-27", "resultsFirstPostDateStruct": {"date": "2023-05-24", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2023-04-27", "lastUpdatePostDateStruct": {"date": "2023-05-24", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Windtree Therapeutics", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "To assess the safety, tolerability and efficacy of two different doses of istaroxime, a new agent with lusitropic and inotropic activities that improves the cardiac contraction-relaxation cycle. The 2 doses of istaroxime (0.5 and 1.0 \u00b5g/kg/min) will be infused via i. v. for 24 hours in comparison with placebo, in treatment of Chinese and Italian patients with Acute Decompensated Heart Failure.", "detailedDescription": "To assess the safety, tolerability and efficacy of two different doses of istaroxime (0.5 and 1.0 \u00b5g/kg/min) in comparison with placebo, including cardiovascular and renal tolerability, as well as changes in biological markers such as N-terminal prohormone brain natriuretic peptide (NT-proBNP) and troponin T (cTnT). The study will be conducted in 96 Chinese and Italian patients with Acute Decompensated Heart Failure. This is a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel group study. Patients were randomly assigned to one of two doses of istaroxime or placebo in a 2:1 ratio within two sequential cohorts of 60 patients each. This 31-day study includes a screening period (Days -1), a treatment period (Day 1), a post-treatment period (Days 2-4), and a follow-up period (which includes one patient visit on Day 30).\n\nIn all the Italian patients and in a subset of Chinese patients pharmacokinetics and metabolism of istaroxime shall also be studied."}, "conditionsModule": {"conditions": ["Acute Decompensated Heart Failure"], "keywords": ["safety", "efficacy", "istaroxime"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "interventionModelDescription": "Cohort I: Participants enrolled in a 2:1 ratio to istaroxime 0.5 \u00b5g/kg/min or placebo.\n\nCohort II: Participants enrolled in a 2:1 ratio to istaroxime 1.0 \u00b5g/kg/min or placebo.\n\nCohort I was enrolled first, followed by Cohort II.", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "QUADRUPLE", "maskingDescription": "Double-blind", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR", "OUTCOMES_ASSESSOR"]}}, "enrollmentInfo": {"count": 120, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "IV infusion of placebo for 24 hours", "interventionNames": ["Drug: Placebo"]}, {"label": "Istaroxime 0.5 \u00b5g/kg/min", "type": "EXPERIMENTAL", "description": "The istaroxime treatment dosed at 0.5 \u00b5g/kg/min via IV infusion for 24 hours", "interventionNames": ["Drug: Istaroxime"]}, {"label": "Istaroxime 1.0 \u00b5g/kg/min", "type": "EXPERIMENTAL", "description": "The istaroxime treatment dosed at 1.0 \u00b5g/kg/min via IV infusion for 24 hours", "interventionNames": ["Drug: Istaroxime"]}], "interventions": [{"type": "DRUG", "name": "Placebo", "description": "IV of matching saline solution", "armGroupLabels": ["Placebo"]}, {"type": "DRUG", "name": "Istaroxime", "description": "IV infusion of 0.5 \u00b5g/kg/min or 1.0 \u00b5g/kg/min istaroxime", "armGroupLabels": ["Istaroxime 0.5 \u00b5g/kg/min", "Istaroxime 1.0 \u00b5g/kg/min"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change in E/Ea Ratio", "description": "Change from baseline at 24 hours in the unitless ratio of E (cm/sec) to Ea (or e') (cm/sec) as measured by echocardiogram.\n\nThe endpoint is the Tissue Doppler echocardiography showing measurement of mitral E/Ea ratio for assessment of diastolic dysfunction. Initially mitral E wave is measured. After that, color Tissue Doppler (tissue velocity imaging or TVI) mode is switched on to assess tissue Doppler. The cursor is placed over the medial mitral annulus and tissue Doppler tracing obtained. This allows Ea velocity to be measured. Higher values are suggestive of a worse outcome; less than 8 is normal.", "timeFrame": "24 hours"}], "secondaryOutcomes": [{"measure": "Change in LVEF", "description": "Change from baseline at 24 hours in LV ejection fraction (LVEF) by tissue Doppler", "timeFrame": "24 hours"}, {"measure": "Change in SVI", "description": "Change from baseline at 24 hours in stroke volume index (SVI) by tissue Doppler", "timeFrame": "24 hours"}, {"measure": "Change in E/A Ratio", "description": "Change from baseline at 24 hours in E/A ratio by tissue Doppler", "timeFrame": "24 hours"}, {"measure": "Change in LV End Systolic Volume", "description": "Change from baseline in left ventricular end systolic volume (LVESV) by tissue Doppler", "timeFrame": "24 hours"}, {"measure": "Change in LV End Diastolic Volume", "description": "Change from baseline in left ventricular end diastolic volume (LVEDV) by tissue Doppler", "timeFrame": "24 hours"}, {"measure": "Change in Dyspnea", "description": "Measured using a visual analog scale (0 to 100). Higher scores indicate less dyspnea.", "timeFrame": "24 hours"}], "otherOutcomes": [{"measure": "Change in cTnT", "description": "Safety endpoint: Changes in troponin (cTnT)", "timeFrame": "24 hours"}, {"measure": "Change in eGFR", "description": "Safety endpoint: Change from baseline in estimated glomerular filtration rate (eGFR)", "timeFrame": "24 Hours"}, {"measure": "Participants With Clinically or Hemodynamically Significant Episodes of Arrhythmias", "description": "Safety endpoint: Number of participants with incidence of clinically or hemodynamically significant episodes of supraventricular or ventricular arrhythmias detected by continuous ECG dynamic monitoring", "timeFrame": "24 hours"}, {"measure": "PR Interval", "description": "Safety Endpoint: The PR interval, measured in milliseconds, extends from the beginning of the P wave (the onset of atrial depolarization) until the beginning of the QRS complex (the onset of ventricular depolarization).", "timeFrame": "24 Hours"}, {"measure": "QRS Duration", "description": "Safety endpoint: The quasi-random signal (QRS) duration represents the time for ventricular depolarization, normally 0.06 to 0.10 seconds.", "timeFrame": "24 hours"}, {"measure": "QTc Interval", "description": "Safety Endpoint: The corrected QT interval (QTc) on an ECG represents the duration in milliseconds of the ventricular action potential, which physiologically correlates with the duration of the ventricular depolarization and repolarization.", "timeFrame": "24 Hours"}, {"measure": "All-Cause Mortality at Day 30", "description": "Safety endpoint: Mortality at Day 30", "timeFrame": "30 days"}, {"measure": "RBC - Shift", "description": "Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in red blood cells (RBC)", "timeFrame": "Day 3"}, {"measure": "Hematocrit - Shift", "description": "Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in hematocrit", "timeFrame": "Day 3"}, {"measure": "Hemoglobin - Shift", "description": "Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in hemoglobin", "timeFrame": "Day 3"}, {"measure": "White Blood Cells (WBC) - Shift", "description": "Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in WBC", "timeFrame": "Day 3"}, {"measure": "Platelets - Shift", "description": "Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in platelets", "timeFrame": "Day 3"}, {"measure": "Potassium - Shift", "description": "Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in potassium", "timeFrame": "Day 3"}, {"measure": "Sodium - Shift", "description": "Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in sodium", "timeFrame": "Day 3"}, {"measure": "Calcium - Shift", "description": "Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in calcium", "timeFrame": "Day 3"}, {"measure": "BUN - Shift", "description": "Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in blood urea nitrogen (BUN)", "timeFrame": "Day 3"}, {"measure": "ALT - Shift", "description": "Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in alanine aminotransferase (ALT)", "timeFrame": "Day 3"}, {"measure": "AST - Shift", "description": "Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in aspartate aminotransferase (AST)", "timeFrame": "Day 3"}, {"measure": "Total Bilirubin - Shift", "description": "Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in total bilirubin", "timeFrame": "Day 3"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\nPatients who fulfill the following inclusion criteria at screening will be considered for the study:\n\n1. Signed informed consent;\n2. Male or female patients 18-85 years (inclusive);\n3. Admission for a recurrent acute decompensated heart failure (ADHF) episode with dyspnea at rest or minimal exertion and need of intravenous diuretic therapy (\u226540 mg iv. furosemide);\n4. Systolic blood pressure between 90 and 125 mmHg (limits included) without signs or symptoms of hypoperfusion including cardiogenic shock, cold extremities and peripheral vasoconstriction, oliguria/anuria, signs of cerebral hypo perfusion such as confusion;\n5. Left ventricular (LV) Ejection fraction (EF) \u2264 40 % measured by 2D-Echocardiography\n6. E/Ea ratio \\>10\n7. BNP \u2265 350pg/mL or NT-pro-BNP \u22651400 pg/mL\n8. Adequate echocardiography window (defined as visualization of at least 13/16 segment of the left ventricle);\n\nExclusion Criteria:\n\nAny of the following criteria established at screening would render a patient ineligible for the study:\n\n1. Pregnant or breast-feeding women (women of child bearing potential must have the results of a negative pregnancy test recorded prior to study drug administration)\n2. Current (within 12 hours prior to screening) or planned (through the completion of study drug infusion) treatment with any iv. therapies, including vasodilators (including nitrates or nesiritide), positive inotropic agents and vasopressors\n3. Current or need of mechanical support (intra-aortic balloon pump, endotracheal intubation, mechanical ventilation, or any ventricular assist device),\n4. Ongoing treatment with oral digoxin. Patient treated with digoxin within the last week, can be randomised if the plasma concentration of digoxin is tested before randomization and its value will be less than 0.5 ng/ml.\n5. History of hypersensitivity to the study medication or any related medication\n6. Diagnosis of cardiogenic shock within the past month;\n7. Acute coronary syndrome or stroke within the past 3 months;\n8. Coronary artery bypass graft or percutaneous coronary intervention within the past month or planned in the next month;\n9. Primary hypertrophic or restrictive cardiomyopathy or systemic illness known to be associated with infiltrative heart disease;\n10. Cor pulmonale or other causes of right-sided heart failure (HF) not related to left ventricular dysfunction;\n11. Pericardial constriction or active pericarditis;\n12. Atrial fibrillation with marked irregularities of heart rhythm;\n13. Life threatening ventricular arrhythmia or implantable cardioverter-defibrillator (ICD) shock within the past month;\n14. Cardiac resynchronization therapy (CRT), ICD, or pacemaker implantation within the past month;\n15. Valvular disease as primary cause of HF;\n16. Heart rate \\>120 bpm or \\< 50 bpm\n17. Acute respiratory distress syndrome or ongoing sepsis;\n18. Fever \\>38\u00b0\n19. History of bronchial asthma or porphyria;\n20. Donation or loss of blood equal to or exceeding 500 mL, during the 8 weeks before administration of study medication;\n21. Positive testing for HIV, Hepatitis B and/or Hepatitis C;\n22. Participation in another interventional study within the past 30 days;\n23. The following laboratory exclusion criteria, verified based on results obtained within the last 24 hours of hospitalization:\n\n    1. Serum creatinine \\> 3.0 mg/dl (\\> 265 \u00b5mol/L);\n    2. Aspartate aminotransferase (ASAT) or alanine aminotransferase (ALAT) \\> 3 x upper limit of normal,\n    3. Hemoglobin (Hb) \\< 10 g/dL,\n    4. Platelet count \\< 100,000/\u00b5L,\n    5. Serum potassium \\> 5.3 mmol/L or \\< 3.8 mmol/L,", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "85 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Giuseppe Bianchi, MD", "affiliation": "Windtree Therapeutics, Inc.", "role": "PRINCIPAL_INVESTIGATOR"}], "locations": [{"facility": "Lanzhou University No.2 Hospital", "city": "Lanzhou", "state": "Gansu", "country": "China", "geoPoint": {"lat": 36.05701, "lon": 103.83987}}, {"facility": "The First Hospital of Lanzhou University", "city": "Lanzhou", "state": "Gansu", "country": "China", "geoPoint": {"lat": 36.05701, "lon": 103.83987}}, {"facility": "Renmin Hospital of Wuhan University", "city": "Wuhan", "state": "Hubei", "country": "China", "geoPoint": {"lat": 30.58333, "lon": 114.26667}}, {"facility": "Jiangsu Province People's Hospital", "city": "Nanjing", "state": "Jiangsu", "country": "China", "geoPoint": {"lat": 32.06167, "lon": 118.77778}}, {"facility": "The General Hospital Of Shenyang Military Region", "city": "Shenyang", "state": "Liaoning", "country": "China", "geoPoint": {"lat": 41.79222, "lon": 123.43278}}, {"facility": "The First Affiliated Hospital Of Xi'an Jiaotong University", "city": "Xi'an", "state": "Shaanxi", "country": "China", "geoPoint": {"lat": 34.25833, "lon": 108.92861}}, {"facility": "Fuwai Hospital Chinese Academy of Medical Sciences", "city": "Beijing", "zip": "100037", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "Beijing Chao Yang Hospital", "city": "Beijing", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "The 307th Hospital of Chinese People's Liberation Army", "city": "Beijing", "country": "China", "geoPoint": {"lat": 39.9075, "lon": 116.39723}}, {"facility": "University and Civil Hospital of Brescia", "city": "Brescia", "country": "Italy", "geoPoint": {"lat": 45.53558, "lon": 10.21472}}, {"facility": "University of Milano-Bicocca", "city": "Milan", "country": "Italy", "geoPoint": {"lat": 45.46427, "lon": 9.18951}}]}, "referencesModule": {"references": [{"pmid": "31975496", "type": "RESULT", "citation": "Carubelli V, Zhang Y, Metra M, Lombardi C, Felker GM, Filippatos G, O'Connor CM, Teerlink JR, Simmons P, Segal R, Malfatto G, La Rovere MT, Li D, Han X, Yuan Z, Yao Y, Li B, Lau LF, Bianchi G, Zhang J; Istaroxime ADHF Trial Group. Treatment with 24 hour istaroxime infusion in patients hospitalised for acute heart failure: a randomised, placebo-controlled trial. Eur J Heart Fail. 2020 Sep;22(9):1684-1693. doi: 10.1002/ejhf.1743. Epub 2020 Jan 23."}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"preAssignmentDetails": "Screening to assess whether the patient qualified for the study. 144 patients were screened, 22 were determined to be screen failures and additional 2 patients were excluded for not meeting inclusion/exclusion criteria.", "groups": [{"id": "FG000", "title": "Placebo", "description": "IV infusion for 24 hours\n\nPlacebo: IV of matching saline solution"}, {"id": "FG001", "title": "Istaroxime 0.5 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 0.5 \u00b5g/kg/min"}, {"id": "FG002", "title": "Istaroxime 1.0 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 1.0 \u00b5g/kg/min"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "39"}, {"groupId": "FG001", "numSubjects": "41"}, {"groupId": "FG002", "numSubjects": "40"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "35"}, {"groupId": "FG001", "numSubjects": "39"}, {"groupId": "FG002", "numSubjects": "33"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "7"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "5"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "Intent-to-Treat", "groups": [{"id": "BG000", "title": "Placebo", "description": "IV infusion for 24 hours\n\nPlacebo: IV of matching saline solution"}, {"id": "BG001", "title": "Istaroxime 0.5 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 0.5 \u00b5g/kg/min"}, {"id": "BG002", "title": "Istaroxime 1.0 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 1.0 \u00b5g/kg/min"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "39"}, {"groupId": "BG001", "value": "41"}, {"groupId": "BG002", "value": "40"}, {"groupId": "BG003", "value": "120"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "39"}, {"groupId": "BG001", "value": "41"}, {"groupId": "BG002", "value": "40"}, {"groupId": "BG003", "value": "120"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "56.67", "spread": "16.21"}, {"groupId": "BG001", "value": "59.73", "spread": "15.53"}, {"groupId": "BG002", "value": "52.23", "spread": "13.02"}, {"groupId": "BG003", "value": "56.24", "spread": "14.98"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "39"}, {"groupId": "BG001", "value": "41"}, {"groupId": "BG002", "value": "40"}, {"groupId": "BG003", "value": "120"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "7"}, {"groupId": "BG002", "value": "6"}, {"groupId": "BG003", "value": "18"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "34"}, {"groupId": "BG001", "value": "34"}, {"groupId": "BG002", "value": "34"}, {"groupId": "BG003", "value": "102"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "39"}, {"groupId": "BG001", "value": "41"}, {"groupId": "BG002", "value": "40"}, {"groupId": "BG003", "value": "120"}]}], "categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "32"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "40"}, {"groupId": "BG003", "value": "96"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "24"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Region of Enrollment", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "China", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "39"}, {"groupId": "BG001", "value": "41"}, {"groupId": "BG002", "value": "40"}, {"groupId": "BG003", "value": "120"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "32"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "40"}, {"groupId": "BG003", "value": "96"}]}]}, {"title": "Italy", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "39"}, {"groupId": "BG001", "value": "41"}, {"groupId": "BG002", "value": "40"}, {"groupId": "BG003", "value": "120"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "7"}, {"groupId": "BG001", "value": "17"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "24"}]}]}]}, {"title": "E/Ea Ratio", "description": "Unitless ratio of E (cm/sec) to Ea (cm/sec) as measured by echocardiogram. The endpoint is the Tissue Doppler echocardiography showing measurement of mitral E/e' ratio for assessment of diastolic dysfunction. Initially mitral E wave is measured. After that, color Tissue Doppler (tissue velocity imaging or TVI) mode is switched on to assess tissue Doppler. The cursor is placed over the medial mitral annulus and tissue Doppler tracing obtained. This allows e' velocity to be measured. Higher values are suggestive of a worse outcome; less than 8 is normal.", "populationDescription": "Measurements for 1 istaroxime 0.5 \u00b5g/kg/min participant not recorded (missing).", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Unitless ratio", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "39"}, {"groupId": "BG001", "value": "40"}, {"groupId": "BG002", "value": "40"}, {"groupId": "BG003", "value": "119"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "17.0", "spread": "5.33"}, {"groupId": "BG001", "value": "20.4", "spread": "7.87"}, {"groupId": "BG002", "value": "15.1", "spread": "5.48"}, {"groupId": "BG003", "value": "17.5", "spread": "6.36"}]}]}]}, {"title": "Left ventricular ejection fraction (LVEF)", "description": "LVEF (% blood ejected from heart) as measured by echocardiogram", "populationDescription": "Measurements for 4 participants (1 placebo participant, 1 istaroxime 0.5 \u00b5g/kg/min participant, 2 istaroxime 1.0 \u00b5g/kg/min participants) not recorded (missing)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "% of blood in heart pumped", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "38"}, {"groupId": "BG001", "value": "40"}, {"groupId": "BG002", "value": "38"}, {"groupId": "BG003", "value": "116"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "26.2", "spread": "7.4"}, {"groupId": "BG001", "value": "27.4", "spread": "6.7"}, {"groupId": "BG002", "value": "28.7", "spread": "7.2"}, {"groupId": "BG003", "value": "27.4", "spread": "7.1"}]}]}]}, {"title": "Stroke Volume Index", "description": "Stroke volume index (SVI) as measured by echocardiogram", "populationDescription": "Measurements for 2 participants (1 istaroxime 0.5 \u00b5g/kg/min participant, 1 istaroxime 1.0 \u00b5g/kg/min participant) not recorded (missing)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "ml/m\u00b2", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "39"}, {"groupId": "BG001", "value": "40"}, {"groupId": "BG002", "value": "39"}, {"groupId": "BG003", "value": "118"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "21.6", "spread": "7.73"}, {"groupId": "BG001", "value": "25.9", "spread": "7.10"}, {"groupId": "BG002", "value": "17.1", "spread": "5.69"}, {"groupId": "BG003", "value": "21.6", "spread": "6.89"}]}]}]}, {"title": "Dyspnea", "description": "Scores on a scale using Visual Analog Scales (VAS). Scores range from 0 to 100, with higher values indicating a better outcome (less dyspnea).", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Scores on a scale", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "39"}, {"groupId": "BG001", "value": "41"}, {"groupId": "BG002", "value": "40"}, {"groupId": "BG003", "value": "120"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "70.8", "spread": "21.32"}, {"groupId": "BG001", "value": "73.6", "spread": "19.49"}, {"groupId": "BG002", "value": "71.5", "spread": "20.95"}, {"groupId": "BG003", "value": "72.0", "spread": "20.59"}]}]}]}, {"title": "Troponin (cTnT)", "description": "Cardiac muscle troponin T (cTnT) measured as ng/L", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "ng/L", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "39"}, {"groupId": "BG001", "value": "41"}, {"groupId": "BG002", "value": "40"}, {"groupId": "BG003", "value": "120"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "33.5", "spread": "33.9"}, {"groupId": "BG001", "value": "34.2", "spread": "36.6"}, {"groupId": "BG002", "value": "40.4", "spread": "78.3"}, {"groupId": "BG003", "value": "36.0", "spread": "53.6"}]}]}]}, {"title": "eGFR", "description": "Estimated glomerular filtration rate (eGFR), measured as ml/min/1.73\u00b7m\u00b2", "populationDescription": "Measurements for 1 istaroxime 0.5 \u00b5g/kg/min participant not recorded (missing)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "ml/min/1.73\u00b7m\u00b2", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "39"}, {"groupId": "BG001", "value": "40"}, {"groupId": "BG002", "value": "40"}, {"groupId": "BG003", "value": "119"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "78.1", "spread": "38.33"}, {"groupId": "BG001", "value": "72.3", "spread": "30.93"}, {"groupId": "BG002", "value": "81.3", "spread": "27.01"}, {"groupId": "BG003", "value": "77.2", "spread": "32.36"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change in E/Ea Ratio", "description": "Change from baseline at 24 hours in the unitless ratio of E (cm/sec) to Ea (or e') (cm/sec) as measured by echocardiogram.\n\nThe endpoint is the Tissue Doppler echocardiography showing measurement of mitral E/Ea ratio for assessment of diastolic dysfunction. Initially mitral E wave is measured. After that, color Tissue Doppler (tissue velocity imaging or TVI) mode is switched on to assess tissue Doppler. The cursor is placed over the medial mitral annulus and tissue Doppler tracing obtained. This allows Ea velocity to be measured. Higher values are suggestive of a worse outcome; less than 8 is normal.", "populationDescription": "Intent-to-Treat", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Unitless ratio", "timeFrame": "24 hours", "groups": [{"id": "OG000", "title": "Istaroxime 0.5 \u00b5g/kg/Min", "description": "Istaroxime participants receiving 0.5 \u00b5g/kg/min (Cohort I)"}, {"id": "OG001", "title": "Placebo Cohort I", "description": "Placebo participants enrolled in Cohort I"}, {"id": "OG002", "title": "Istaroxime 1.0 \u00b5g/kg/Min", "description": "Istaroxime participants receiving 1.0 \u00b5g/kg/min (Cohort II)"}, {"id": "OG003", "title": "Placebo Cohort II", "description": "Placebo participants enrolled in Cohort II"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "19"}, {"groupId": "OG002", "value": "40"}, {"groupId": "OG003", "value": "20"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-4.55", "lowerLimit": "-6.05", "upperLimit": "-3.04"}, {"groupId": "OG001", "value": "-1.55", "lowerLimit": "-3.77", "upperLimit": "0.67"}, {"groupId": "OG002", "value": "-3.16", "lowerLimit": "-4.09", "upperLimit": "-2.24"}, {"groupId": "OG003", "value": "-1.08", "lowerLimit": "-2.30", "upperLimit": "0.13"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: No difference in E/Ea ratio between istaroxime and placebo", "nonInferiorityType": "SUPERIORITY", "pValue": "0.029", "pValueComment": "Alpha set at 0.05.", "statisticalMethod": "ANOVA", "statisticalComment": "Treatment term included in the model", "paramType": "Mean Difference (Final Values)", "paramValue": "-3.00", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.68", "ciUpperLimit": "-0.32"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Null hypothesis: No difference in E/Ea ratio between istaroxime and placebo", "nonInferiorityType": "SUPERIORITY", "pValue": "0.009", "pValueComment": "Alpha set at 0.05.", "statisticalMethod": "ANOVA", "statisticalComment": "Treatment term included in the model", "paramType": "Mean Difference (Final Values)", "paramValue": "-2.08", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.61", "ciUpperLimit": "-0.55"}]}, {"type": "SECONDARY", "title": "Change in LVEF", "description": "Change from baseline at 24 hours in LV ejection fraction (LVEF) by tissue Doppler", "populationDescription": "Intent-to-Treat", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "% of blood leaving the heart", "timeFrame": "24 hours", "groups": [{"id": "OG000", "title": "Istaroxime 0.5 \u00b5g/kg/Min", "description": "Istaroxime participants receiving 0.5 \u00b5g/kg/min (Cohort I)"}, {"id": "OG001", "title": "Placebo Cohort I", "description": "Placebo participants enrolled in Cohort I"}, {"id": "OG002", "title": "Istaroxime 1.0 \u00b5g/kg/Min", "description": "Istaroxime participants receiving 1.0 \u00b5g/kg/min (Cohort II)"}, {"id": "OG003", "title": "Placebo Cohort II", "description": "Placebo participants enrolled in Cohort II"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "19"}, {"groupId": "OG002", "value": "40"}, {"groupId": "OG003", "value": "20"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3.026", "lowerLimit": "1.850", "upperLimit": "4.203"}, {"groupId": "OG001", "value": "1.263", "lowerLimit": "-0.401", "upperLimit": "2.927"}, {"groupId": "OG002", "value": "3.818", "lowerLimit": "2.362", "upperLimit": "5.275"}, {"groupId": "OG003", "value": "2.833", "lowerLimit": "0.861", "upperLimit": "4.805"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: No difference in LVEF % between istaroxime and placebo participants.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.089", "pValueComment": "Alpha set at 0.05. No adjustment for multiple comparisons", "statisticalMethod": "ANOVA", "statisticalComment": "Treatment term included in the model", "paramType": "Mean Difference (Final Values)", "paramValue": "1.7632", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.2751", "ciUpperLimit": "3.8014"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Null hypothesis: No difference in LVEF % between istaroxime and placebo participants.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.423", "pValueComment": "Alpha set at 0.05. No adjustment for multiple comparisons", "statisticalMethod": "ANOVA", "statisticalComment": "Treatment term included in the model", "paramType": "Mean Difference (Final Values)", "paramValue": "0.9848", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.4668", "ciUpperLimit": "3.4365"}]}, {"type": "SECONDARY", "title": "Change in SVI", "description": "Change from baseline at 24 hours in stroke volume index (SVI) by tissue Doppler", "populationDescription": "Intent-to-Treat", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mL/m\u00b2", "timeFrame": "24 hours", "groups": [{"id": "OG000", "title": "Istaroxime 0.5 \u00b5g/kg/Min", "description": "Istaroxime participants receiving 0.5 \u00b5g/kg/min (Cohort I)"}, {"id": "OG001", "title": "Placebo Cohort I", "description": "Placebo participants enrolled in Cohort I"}, {"id": "OG002", "title": "Istaroxime 1.0 \u00b5g/kg/Min", "description": "Istaroxime participants receiving 1.0 \u00b5g/kg/min (Cohort II)"}, {"id": "OG003", "title": "Placebo Cohort II", "description": "Placebo participants enrolled in Cohort II"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "19"}, {"groupId": "OG002", "value": "40"}, {"groupId": "OG003", "value": "20"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.334", "lowerLimit": "3.371", "upperLimit": "7.296"}, {"groupId": "OG001", "value": "1.649", "lowerLimit": "-1.126", "upperLimit": "4.425"}, {"groupId": "OG002", "value": "5.488", "lowerLimit": "3.882", "upperLimit": "7.094"}, {"groupId": "OG003", "value": "3.178", "lowerLimit": "1.030", "upperLimit": "5.327"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: No difference in SVI between istaroxime and placebo participants.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.034", "pValueComment": "Alpha set at 0.05. No adjustment for multiple comparisons", "statisticalMethod": "ANOVA", "statisticalComment": "Treatment term is in the model.", "paramType": "Mean Difference (Final Values)", "paramValue": "3.684", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.285", "ciUpperLimit": "7.083"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Null hypothesis: No difference in E to A ratio between istaroxime and placebo participants.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.090", "pValueComment": "Alpha set at 0.05. No adjustment for multiple comparisons", "statisticalMethod": "ANOVA", "statisticalComment": "Treatment term is in the model", "paramType": "Mean Difference (Final Values)", "paramValue": "2.310", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.373", "ciUpperLimit": "4.992"}]}, {"type": "SECONDARY", "title": "Change in E/A Ratio", "description": "Change from baseline at 24 hours in E/A ratio by tissue Doppler", "populationDescription": "Intent-to-Treat", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Unitless ratio", "timeFrame": "24 hours", "groups": [{"id": "OG000", "title": "Istaroxime 0.5 \u00b5g/kg/Min", "description": "Istaroxime participants receiving 0.5 \u00b5g/kg/min (Cohort I)"}, {"id": "OG001", "title": "Placebo Cohort I", "description": "Placebo participants enrolled in Cohort I"}, {"id": "OG002", "title": "Istaroxime 1.0 \u00b5g/kg/Min", "description": "Istaroxime participants receiving 1.0 \u00b5g/kg/min (Cohort II)"}, {"id": "OG003", "title": "Placebo Cohort II", "description": "Placebo participants enrolled in Cohort II"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "19"}, {"groupId": "OG002", "value": "40"}, {"groupId": "OG003", "value": "20"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.643", "lowerLimit": "-1.091", "upperLimit": "-0.197"}, {"groupId": "OG001", "value": "0.133", "lowerLimit": "-0.463", "upperLimit": "0.729"}, {"groupId": "OG002", "value": "-0.654", "lowerLimit": "-1.093", "upperLimit": "-0.216"}, {"groupId": "OG003", "value": "0.175", "lowerLimit": "-0.419", "upperLimit": "0.769"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: No difference in E to A ratio between istaroxime and placebo participants.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.042", "pValueComment": "Alpha set at 0.05. No adjustment for multiple comparisons", "statisticalMethod": "ANOVA", "statisticalComment": "Treatment term is included in the model", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.777", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.522", "ciUpperLimit": "-0.032"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Null hypothesis: No difference in E to A ratio between istaroxime and placebo participants.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.029", "pValueComment": "Alpha set at 0.05. No adjustment for multiple comparisons", "statisticalMethod": "ANOVA", "statisticalComment": "Treatment term is in the model", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.829", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.568", "ciUpperLimit": "-0.091"}]}, {"type": "SECONDARY", "title": "Change in LV End Systolic Volume", "description": "Change from baseline in left ventricular end systolic volume (LVESV) by tissue Doppler", "populationDescription": "Intent-to-Treat", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mL", "timeFrame": "24 hours", "groups": [{"id": "OG000", "title": "Istaroxime 0.5 \u00b5g/kg/Min", "description": "Istaroxime participants receiving 0.5 \u00b5g/kg/min (Cohort I)"}, {"id": "OG001", "title": "Placebo Cohort I", "description": "Placebo participants enrolled in Cohort I"}, {"id": "OG002", "title": "Istaroxime 1.0 \u00b5g/kg/Min", "description": "Istaroxime participants receiving 1.0 \u00b5g/kg/min (Cohort II)"}, {"id": "OG003", "title": "Placebo Cohort II", "description": "Placebo participants enrolled in Cohort II"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "19"}, {"groupId": "OG002", "value": "40"}, {"groupId": "OG003", "value": "20"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-7.105", "lowerLimit": "-10.933", "upperLimit": "-3.277"}, {"groupId": "OG001", "value": "-1.736", "lowerLimit": "-7.150", "upperLimit": "3.677"}, {"groupId": "OG002", "value": "-11.39", "lowerLimit": "-17.438", "upperLimit": "-5.350"}, {"groupId": "OG003", "value": "-11.83", "lowerLimit": "-20.017", "upperLimit": "-3.649"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: No difference in LVESV between istaroxime and placebo participants.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.110", "pValueComment": "Alpha set at 0.05. No adjustment for multiple comparisons", "statisticalMethod": "ANOVA", "statisticalComment": "Treatment term is in the model", "paramType": "Mean Difference (Final Values)", "paramValue": "-5.368", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-11.999", "ciUpperLimit": "1.262"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Null hypothesis: No difference in LVEDV between istaroxime and placebo participants.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.931", "pValueComment": "Alpha set at 0.05. No adjustment for multiple comparisons", "statisticalMethod": "ANOVA", "statisticalComment": "Treatment term is in the model", "paramType": "Mean Difference (Final Values)", "paramValue": "0.439", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-9.735", "ciUpperLimit": "10.614"}]}, {"type": "SECONDARY", "title": "Change in LV End Diastolic Volume", "description": "Change from baseline in left ventricular end diastolic volume (LVEDV) by tissue Doppler", "populationDescription": "Intent-to-Treat", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mL", "timeFrame": "24 hours", "groups": [{"id": "OG000", "title": "Istaroxime 0.5 \u00b5g/kg/Min", "description": "Istaroxime participants receiving 0.5 \u00b5g/kg/min (Cohort I)"}, {"id": "OG001", "title": "Placebo Cohort I", "description": "Placebo participants enrolled in Cohort I"}, {"id": "OG002", "title": "Istaroxime 1.0 \u00b5g/kg/Min", "description": "Istaroxime participants receiving 1.0 \u00b5g/kg/min (Cohort II)"}, {"id": "OG003", "title": "Placebo Cohort II", "description": "Placebo participants enrolled in Cohort II"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "41"}, {"groupId": "OG001", "value": "19"}, {"groupId": "OG002", "value": "40"}, {"groupId": "OG003", "value": "20"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.710", "lowerLimit": "-4.243", "upperLimit": "2.822"}, {"groupId": "OG001", "value": "0.947", "lowerLimit": "-4.049", "upperLimit": "5.944"}, {"groupId": "OG002", "value": "-3.666", "lowerLimit": "-9.507", "upperLimit": "2.173"}, {"groupId": "OG003", "value": "-7.611", "lowerLimit": "-15.518", "upperLimit": "0.296"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: No difference in E to A ratio between istaroxime and placebo participants.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.589", "pValueComment": "Alpha set at 0.05. No adjustment for multiple comparisons", "statisticalMethod": "ANOVA", "statisticalComment": "Treatment term in the model", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.657", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.777", "ciUpperLimit": "4.461"}, {"groupIds": ["OG002", "OG003"], "groupDescription": "Null hypothesis: No difference in E to A ratio between istaroxime and placebo participants.", "nonInferiorityType": "SUPERIORITY", "pValue": "0.424", "pValueComment": "Alpha set at 0.05. No adjustment for multiple comparisons", "statisticalMethod": "ANOVA", "statisticalComment": "Treatment term is in the model.", "paramType": "Mean Difference (Final Values)", "paramValue": "3.944", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.886", "ciUpperLimit": "13.774"}]}, {"type": "SECONDARY", "title": "Change in Dyspnea", "description": "Measured using a visual analog scale (0 to 100). Higher scores indicate less dyspnea.", "populationDescription": "Intent-to-Treat", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "Score on a scale (Visual Analog Scale)", "timeFrame": "24 hours", "groups": [{"id": "OG000", "title": "Placebo", "description": "IV infusion for 24 hours\n\nPlacebo: IV of matching saline solution"}, {"id": "OG001", "title": "Istaroxime 0.5 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 0.5 \u00b5g/kg/min"}, {"id": "OG002", "title": "Istaroxime 1.0 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 1.0 \u00b5g/kg/min"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "41"}, {"groupId": "OG002", "value": "40"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "9.75", "spread": "11.80"}, {"groupId": "OG001", "value": "9.14", "spread": "10.08"}, {"groupId": "OG002", "value": "12.09", "spread": "14.79"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis: no difference between treatment groups", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Linear mixed model with treatment, center, timepoint, gender, baseline cTnT value, atrial fibrillation, and treatment\\*timepoint interaction included in the model.", "pValue": "0.987", "pValueComment": "Unadjusted alpha of 0.05 is the threshold for statistical significance.", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Kenward-Roger adjustment used for the degrees of freedom.", "paramType": "Mean Difference (Final Values)", "paramValue": "-0.041", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.216", "ciUpperLimit": "5.133"}, {"groupIds": ["OG000", "OG002"], "groupDescription": "Null hypothesis: no difference between treatment groups.", "nonInferiorityType": "SUPERIORITY", "nonInferiorityComment": "Linear mixed model with treatment, center, timepoint, gender, baseline cTnT value, atrial fibrillation, and treatment\\*timepoint interaction included in the model.", "pValue": "0.251", "pValueComment": "Unadjusted alpha of 0.05 is the threshold for statistical significance.", "statisticalMethod": "Mixed Models Analysis", "statisticalComment": "Kenward-Roger adjustment used for the degrees of freedom.", "paramType": "Mean Difference (Final Values)", "paramValue": "3.015", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.168", "ciUpperLimit": "8.198"}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change in cTnT", "description": "Safety endpoint: Changes in troponin (cTnT)", "populationDescription": "Intent-to-Treat", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ng/L", "timeFrame": "24 hours", "groups": [{"id": "OG000", "title": "Placebo", "description": "IV infusion for 24 hours\n\nPlacebo: IV of matching saline solution"}, {"id": "OG001", "title": "Istaroxime 0.5 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 0.5 \u00b5g/kg/min"}, {"id": "OG002", "title": "Istaroxime 1.0 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 1.0 \u00b5g/kg/min"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "41"}, {"groupId": "OG002", "value": "40"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.23", "spread": "10.83"}, {"groupId": "OG001", "value": "0.51", "spread": "7.58"}, {"groupId": "OG002", "value": "-4.06", "spread": "49.97"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Change in eGFR", "description": "Safety endpoint: Change from baseline in estimated glomerular filtration rate (eGFR)", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "ml/min/1.73\u00b7m\u00b2", "timeFrame": "24 Hours", "groups": [{"id": "OG000", "title": "Placebo", "description": "IV infusion for 24 hours\n\nPlacebo: IV of matching saline solution"}, {"id": "OG001", "title": "Istaroxime 0.5 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 0.5 \u00b5g/kg/min"}, {"id": "OG002", "title": "Istaroxime 1.0 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 1.0 \u00b5g/kg/min"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "41"}, {"groupId": "OG002", "value": "40"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.60", "spread": "14.71"}, {"groupId": "OG001", "value": "5.19", "spread": "16.25"}, {"groupId": "OG002", "value": "7.65", "spread": "13.22"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Participants With Clinically or Hemodynamically Significant Episodes of Arrhythmias", "description": "Safety endpoint: Number of participants with incidence of clinically or hemodynamically significant episodes of supraventricular or ventricular arrhythmias detected by continuous ECG dynamic monitoring", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "24 hours", "groups": [{"id": "OG000", "title": "Placebo", "description": "IV infusion for 24 hours\n\nPlacebo: IV of matching saline solution"}, {"id": "OG001", "title": "Istaroxime 0.5 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 0.5 \u00b5g/kg/min"}, {"id": "OG002", "title": "Istaroxime 1.0 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 1.0 \u00b5g/kg/min"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "41"}, {"groupId": "OG002", "value": "40"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "4"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "PR Interval", "description": "Safety Endpoint: The PR interval, measured in milliseconds, extends from the beginning of the P wave (the onset of atrial depolarization) until the beginning of the QRS complex (the onset of ventricular depolarization).", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "msec", "timeFrame": "24 Hours", "groups": [{"id": "OG000", "title": "Placebo", "description": "IV infusion for 24 hours\n\nPlacebo: IV of matching saline solution"}, {"id": "OG001", "title": "Istaroxime 0.5 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 0.5 \u00b5g/kg/min"}, {"id": "OG002", "title": "Istaroxime 1.0 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 1.0 \u00b5g/kg/min"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "41"}, {"groupId": "OG002", "value": "40"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "184.0", "spread": "31.27"}, {"groupId": "OG001", "value": "179.2", "spread": "28.11"}, {"groupId": "OG002", "value": "169.41", "spread": "32.72"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "QRS Duration", "description": "Safety endpoint: The quasi-random signal (QRS) duration represents the time for ventricular depolarization, normally 0.06 to 0.10 seconds.", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "msec", "timeFrame": "24 hours", "groups": [{"id": "OG000", "title": "Placebo", "description": "IV infusion for 24 hours\n\nPlacebo: IV of matching saline solution"}, {"id": "OG001", "title": "Istaroxime 0.5 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 0.5 \u00b5g/kg/min"}, {"id": "OG002", "title": "Istaroxime 1.0 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 1.0 \u00b5g/kg/min"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "41"}, {"groupId": "OG002", "value": "40"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "125.2", "spread": "37.11"}, {"groupId": "OG001", "value": "132.5", "spread": "31.59"}, {"groupId": "OG002", "value": "127.6", "spread": "26.65"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "QTc Interval", "description": "Safety Endpoint: The corrected QT interval (QTc) on an ECG represents the duration in milliseconds of the ventricular action potential, which physiologically correlates with the duration of the ventricular depolarization and repolarization.", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "msec", "timeFrame": "24 Hours", "groups": [{"id": "OG000", "title": "Placebo", "description": "IV infusion for 24 hours\n\nPlacebo: IV of matching saline solution"}, {"id": "OG001", "title": "Istaroxime 0.5 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 0.5 \u00b5g/kg/min"}, {"id": "OG002", "title": "Istaroxime 1.0 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 1.0 \u00b5g/kg/min"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "41"}, {"groupId": "OG002", "value": "40"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "472.8", "spread": "41.90"}, {"groupId": "OG001", "value": "480.8", "spread": "55.72"}, {"groupId": "OG002", "value": "486.9", "spread": "40.18"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "All-Cause Mortality at Day 30", "description": "Safety endpoint: Mortality at Day 30", "populationDescription": "Intent-to-Treat", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "30 days", "groups": [{"id": "OG000", "title": "Placebo", "description": "IV infusion for 24 hours\n\nPlacebo: IV of matching saline solution"}, {"id": "OG001", "title": "Istaroxime 0.5 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 0.5 \u00b5g/kg/min"}, {"id": "OG002", "title": "Istaroxime 1.0 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 1.0 \u00b5g/kg/min"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "41"}, {"groupId": "OG002", "value": "40"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "2"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "RBC - Shift", "description": "Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in red blood cells (RBC)", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Day 3", "groups": [{"id": "OG000", "title": "Placebo", "description": "IV infusion for 24 hours\n\nPlacebo: IV of matching saline solution"}, {"id": "OG001", "title": "Istaroxime 0.5 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 0.5 \u00b5g/kg/min"}, {"id": "OG002", "title": "Istaroxime 1.0 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 1.0 \u00b5g/kg/min"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "41"}, {"groupId": "OG002", "value": "40"}]}], "classes": [{"title": "Normal to Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "22"}, {"groupId": "OG001", "value": "17"}, {"groupId": "OG002", "value": "21"}]}]}, {"title": "Normal to Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "4"}]}]}, {"title": "Abnormal to Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "4"}]}]}, {"title": "Abnormal to Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "7"}]}]}, {"title": "Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "4"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Hematocrit - Shift", "description": "Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in hematocrit", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Day 3", "groups": [{"id": "OG000", "title": "Placebo", "description": "IV infusion for 24 hours\n\nPlacebo: IV of matching saline solution"}, {"id": "OG001", "title": "Istaroxime 0.5 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 0.5 \u00b5g/kg/min"}, {"id": "OG002", "title": "Istaroxime 1.0 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 1.0 \u00b5g/kg/min"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "41"}, {"groupId": "OG002", "value": "40"}]}], "classes": [{"title": "Normal to Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "21"}, {"groupId": "OG001", "value": "15"}, {"groupId": "OG002", "value": "17"}]}]}, {"title": "Normal to Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "5"}]}]}, {"title": "Abnormal to Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "6"}]}]}, {"title": "Abnormal to Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "6"}, {"groupId": "OG001", "value": "14"}, {"groupId": "OG002", "value": "8"}]}]}, {"title": "Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "4"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Hemoglobin - Shift", "description": "Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in hemoglobin", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Day 3", "groups": [{"id": "OG000", "title": "Placebo", "description": "IV infusion for 24 hours\n\nPlacebo: IV of matching saline solution"}, {"id": "OG001", "title": "Istaroxime 0.5 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 0.5 \u00b5g/kg/min"}, {"id": "OG002", "title": "Istaroxime 1.0 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 1.0 \u00b5g/kg/min"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "41"}, {"groupId": "OG002", "value": "40"}]}], "classes": [{"title": "Normal to Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "13"}, {"groupId": "OG002", "value": "23"}]}]}, {"title": "Normal to Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "Abnormal to Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "7"}, {"groupId": "OG002", "value": "5"}]}]}, {"title": "Abnormal to Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "8"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "6"}]}]}, {"title": "Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "4"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "White Blood Cells (WBC) - Shift", "description": "Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in WBC", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Day 3", "groups": [{"id": "OG000", "title": "Placebo", "description": "IV infusion for 24 hours\n\nPlacebo: IV of matching saline solution"}, {"id": "OG001", "title": "Istaroxime 0.5 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 0.5 \u00b5g/kg/min"}, {"id": "OG002", "title": "Istaroxime 1.0 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 1.0 \u00b5g/kg/min"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "41"}, {"groupId": "OG002", "value": "40"}]}], "classes": [{"title": "Normal to Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "35"}, {"groupId": "OG001", "value": "30"}, {"groupId": "OG002", "value": "25"}]}]}, {"title": "Normal to Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "6"}]}]}, {"title": "Abnormal to Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "Abnormal to Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "3"}]}]}, {"title": "Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "4"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Platelets - Shift", "description": "Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in platelets", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Day 3", "groups": [{"id": "OG000", "title": "Placebo", "description": "IV infusion for 24 hours\n\nPlacebo: IV of matching saline solution"}, {"id": "OG001", "title": "Istaroxime 0.5 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 0.5 \u00b5g/kg/min"}, {"id": "OG002", "title": "Istaroxime 1.0 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 1.0 \u00b5g/kg/min"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "41"}, {"groupId": "OG002", "value": "40"}]}], "classes": [{"title": "Normal to Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "32"}, {"groupId": "OG002", "value": "31"}]}]}, {"title": "Normal to Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "4"}]}]}, {"title": "Abnormal to Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Abnormal to Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "4"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Potassium - Shift", "description": "Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in potassium", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Day 3", "groups": [{"id": "OG000", "title": "Placebo", "description": "IV infusion for 24 hours\n\nPlacebo: IV of matching saline solution"}, {"id": "OG001", "title": "Istaroxime 0.5 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 0.5 \u00b5g/kg/min"}, {"id": "OG002", "title": "Istaroxime 1.0 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 1.0 \u00b5g/kg/min"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "41"}, {"groupId": "OG002", "value": "40"}]}], "classes": [{"title": "Normal to Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "37"}, {"groupId": "OG001", "value": "40"}, {"groupId": "OG002", "value": "34"}]}]}, {"title": "Normal to Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "Abnormal to Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Abnormal to Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "4"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Sodium - Shift", "description": "Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in sodium", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Day 3", "groups": [{"id": "OG000", "title": "Placebo", "description": "IV infusion for 24 hours\n\nPlacebo: IV of matching saline solution"}, {"id": "OG001", "title": "Istaroxime 0.5 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 0.5 \u00b5g/kg/min"}, {"id": "OG002", "title": "Istaroxime 1.0 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 1.0 \u00b5g/kg/min"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "41"}, {"groupId": "OG002", "value": "40"}]}], "classes": [{"title": "Normal to Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "23"}, {"groupId": "OG001", "value": "21"}, {"groupId": "OG002", "value": "19"}]}]}, {"title": "Normal to Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "12"}, {"groupId": "OG002", "value": "8"}]}]}, {"title": "Abnormal to Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Abnormal to Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "8"}]}]}, {"title": "Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "4"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Calcium - Shift", "description": "Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in calcium", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Day 3", "groups": [{"id": "OG000", "title": "Placebo", "description": "IV infusion for 24 hours\n\nPlacebo: IV of matching saline solution"}, {"id": "OG001", "title": "Istaroxime 0.5 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 0.5 \u00b5g/kg/min"}, {"id": "OG002", "title": "Istaroxime 1.0 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 1.0 \u00b5g/kg/min"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "41"}, {"groupId": "OG002", "value": "40"}]}], "classes": [{"title": "Normal to Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "26"}, {"groupId": "OG002", "value": "20"}]}]}, {"title": "Normal to Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}]}]}, {"title": "Abnormal to Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "9"}]}]}, {"title": "Abnormal to Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "4"}]}]}, {"title": "Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "10"}, {"groupId": "OG002", "value": "6"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "BUN - Shift", "description": "Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in blood urea nitrogen (BUN)", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Day 3", "groups": [{"id": "OG000", "title": "Placebo", "description": "IV infusion for 24 hours\n\nPlacebo: IV of matching saline solution"}, {"id": "OG001", "title": "Istaroxime 0.5 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 0.5 \u00b5g/kg/min"}, {"id": "OG002", "title": "Istaroxime 1.0 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 1.0 \u00b5g/kg/min"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "41"}, {"groupId": "OG002", "value": "40"}]}], "classes": [{"title": "Normal to Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "11"}, {"groupId": "OG001", "value": "13"}, {"groupId": "OG002", "value": "14"}]}]}, {"title": "Normal to Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "7"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "6"}]}]}, {"title": "Abnormal to Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "8"}]}]}, {"title": "Abnormal to Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "14"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "7"}]}]}, {"title": "Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "6"}, {"groupId": "OG002", "value": "5"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "ALT - Shift", "description": "Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in alanine aminotransferase (ALT)", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Day 3", "groups": [{"id": "OG000", "title": "Placebo", "description": "IV infusion for 24 hours\n\nPlacebo: IV of matching saline solution"}, {"id": "OG001", "title": "Istaroxime 0.5 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 0.5 \u00b5g/kg/min"}, {"id": "OG002", "title": "Istaroxime 1.0 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 1.0 \u00b5g/kg/min"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "41"}, {"groupId": "OG002", "value": "40"}]}], "classes": [{"title": "Normal to Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "29"}, {"groupId": "OG001", "value": "31"}, {"groupId": "OG002", "value": "29"}]}]}, {"title": "Normal to Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "Abnormal to Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "2"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "0"}]}]}, {"title": "Abnormal to Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "5"}, {"groupId": "OG002", "value": "5"}]}]}, {"title": "Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "4"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "AST - Shift", "description": "Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in aspartate aminotransferase (AST)", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Day 3", "groups": [{"id": "OG000", "title": "Placebo", "description": "IV infusion for 24 hours\n\nPlacebo: IV of matching saline solution"}, {"id": "OG001", "title": "Istaroxime 0.5 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 0.5 \u00b5g/kg/min"}, {"id": "OG002", "title": "Istaroxime 1.0 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 1.0 \u00b5g/kg/min"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "41"}, {"groupId": "OG002", "value": "40"}]}], "classes": [{"title": "Normal to Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "28"}, {"groupId": "OG001", "value": "28"}, {"groupId": "OG002", "value": "24"}]}]}, {"title": "Normal to Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "1"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "5"}]}]}, {"title": "Abnormal to Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "4"}]}]}, {"title": "Abnormal to Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "4"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "3"}]}]}, {"title": "Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "4"}]}]}]}, {"type": "OTHER_PRE_SPECIFIED", "title": "Total Bilirubin - Shift", "description": "Safety endpoint: Baseline normal/abnormal to Day 3 normal/abnormal in total bilirubin", "populationDescription": "Safety Population", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Day 3", "groups": [{"id": "OG000", "title": "Placebo", "description": "IV infusion for 24 hours\n\nPlacebo: IV of matching saline solution"}, {"id": "OG001", "title": "Istaroxime 0.5 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 0.5 \u00b5g/kg/min"}, {"id": "OG002", "title": "Istaroxime 1.0 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 1.0 \u00b5g/kg/min"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "39"}, {"groupId": "OG001", "value": "41"}, {"groupId": "OG002", "value": "40"}]}], "classes": [{"title": "Normal to Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "21"}, {"groupId": "OG002", "value": "13"}]}]}, {"title": "Normal to Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "2"}]}]}, {"title": "Abnormal to Normal", "categories": [{"measurements": [{"groupId": "OG000", "value": "9"}, {"groupId": "OG001", "value": "3"}, {"groupId": "OG002", "value": "6"}]}]}, {"title": "Abnormal to Abnormal", "categories": [{"measurements": [{"groupId": "OG000", "value": "13"}, {"groupId": "OG001", "value": "11"}, {"groupId": "OG002", "value": "15"}]}]}, {"title": "Missing", "categories": [{"measurements": [{"groupId": "OG000", "value": "5"}, {"groupId": "OG001", "value": "4"}, {"groupId": "OG002", "value": "4"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "3", "timeFrame": "Enrollment to 30 days after enrollment", "description": "Participants were closely supervised in a hospital. Adverse events were observed by study staff and reported by participants.", "eventGroups": [{"id": "EG000", "title": "Placebo", "description": "IV infusion for 24 hours\n\nPlacebo: IV of matching saline solution", "deathsNumAffected": 0, "deathsNumAtRisk": 39, "seriousNumAffected": 2, "seriousNumAtRisk": 39, "otherNumAffected": 23, "otherNumAtRisk": 39}, {"id": "EG001", "title": "Istaroxime 0.5 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 0.5 \u00b5g/kg/min", "deathsNumAffected": 0, "deathsNumAtRisk": 41, "seriousNumAffected": 2, "seriousNumAtRisk": 41, "otherNumAffected": 31, "otherNumAtRisk": 41}, {"id": "EG002", "title": "Istaroxime 1.0 \u00b5g/kg/Min", "description": "Istaroxime via IV infusion for 24 hours\n\nIstaroxime: IV infusion of istaroxime 1.0 \u00b5g/kg/min", "deathsNumAffected": 2, "deathsNumAtRisk": 40, "seriousNumAffected": 6, "seriousNumAtRisk": 40, "otherNumAffected": 33, "otherNumAtRisk": 40}], "seriousEvents": [{"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 40}]}, {"term": "Cardiac failure congestive", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 40}]}, {"term": "Cardiogenic shock", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 40}]}, {"term": "Cardiac death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 40}]}, {"term": "Transient ischaemic attack", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 40}]}, {"term": "Renal embolism", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 40}]}, {"term": "Hyperventilation", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 40}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 40}]}], "otherEvents": [{"term": "Arrythmia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 40}]}, {"term": "Atrial fibrillation", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 40}]}, {"term": "Cardiac failure", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 40}]}, {"term": "Palpitations", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 40}]}, {"term": "Ventricular tachycardia", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 3, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 40}]}, {"term": "Abdominal discomfort", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 40}]}, {"term": "Abdominal distension", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 40}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 40}]}, {"term": "Gastrointestinal disorder", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 40}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 10, "numAffected": 9, "numAtRisk": 40}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 10, "numAffected": 10, "numAtRisk": 40}]}, {"term": "Chest discomfort", "organSystem": "General disorders", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 40}]}, {"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 3, "numAffected": 2, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 40}]}, {"term": "Infusion site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "notes": "Includes \"Implant site pain\", \"Infusion site pain\", and \"Injection site pain\"", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 17, "numAffected": 17, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 12, "numAffected": 12, "numAtRisk": 40}]}, {"term": "Oedema peripheral", "organSystem": "General disorders", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 40}]}, {"term": "Hepatic function abnormal", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 40}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 40}]}, {"term": "Alanine aminotransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 40}]}, {"term": "Bilirubin conjugated increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 40}]}, {"term": "Blood bilirubin increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 4, "numAffected": 4, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 40}]}, {"term": "Blood creatinine increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 40}]}, {"term": "Blood potassium increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 40}]}, {"term": "Blood urea increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 40}]}, {"term": "Blood uric acid increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 3, "numAffected": 3, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 40}]}, {"term": "Electrocardiogram T wave abnormal", "organSystem": "Investigations", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 40}]}, {"term": "Electrocardiogram T wave inversion", "organSystem": "Investigations", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 3, "numAffected": 2, "numAtRisk": 40}]}, {"term": "Gamma-glutamyltransferase increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 40}]}, {"term": "White blood cell count increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 40}]}, {"term": "Hyperkalemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 40}]}, {"term": "Hyponatraemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 40}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 5, "numAffected": 5, "numAtRisk": 40}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 40}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 40}]}, {"term": "Dyspnoea", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 2, "numAffected": 2, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 40}]}, {"term": "Hypotension", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 6, "numAffected": 6, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 40}]}, {"term": "Phlebitis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA, v16.0", "assessmentType": "NON_SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 39}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 41}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 40}]}]}, "moreInfoModule": {"limitationsAndCaveats": {"description": "The major limitation of this study regards enrollment discrepancies between the study populations and sites of the two cohorts, with Cohort 2 enrolling exclusively Asian patients. We observed that patients enrolled in this trial were younger and with a better renal function compared to other studies."}, "certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "All data and results of the clinical study are possessed by sponsor and investigator. Investigator agrees not to submit the results of this study for publication or presentation before the sponsor review the accuracy and no leakage of confidential information in the manuscript."}, "pointOfContact": {"title": "Phillip D. Simmons, Executive Director of Biostatistics & Data Management", "organization": "Windtree Therapeutics, Inc.", "email": "psimmons@windtreetx.com", "phone": "215-488-9300"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2018-01-17", "uploadDate": "2023-01-23T14:41", "filename": "Prot_000.pdf", "size": 1742489}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2018-10-30", "uploadDate": "2023-01-23T14:40", "filename": "SAP_001.pdf", "size": 501014}, {"typeAbbrev": "ICF", "hasProtocol": false, "hasSap": false, "hasIcf": true, "label": "Informed Consent Form", "date": "2017-04-18", "uploadDate": "2023-03-28T12:41", "filename": "ICF_002.pdf", "size": 297764}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000006333", "term": "Heart Failure"}], "ancestors": [{"id": "D000006331", "term": "Heart Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M9421", "name": "Heart Failure", "asFound": "Heart Failure", "relevance": "HIGH"}, {"id": "M9419", "name": "Heart Diseases", "relevance": "LOW"}, {"id": "T170", "name": "Acute Graft Versus Host Disease", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "Rare", "name": "Rare Diseases"}]}, "interventionBrowseModule": {"browseLeaves": [{"id": "M21860", "name": "Pharmaceutical Solutions", "relevance": "LOW"}], "browseBranches": [{"abbrev": "PhSol", "name": "Pharmaceutical Solutions"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}]}}, "hasResults": true}